| **Number of Studies (Participants)** | **Domains Pertaining to Strength of Evidence** | | | | | **Strength of Evidence** |
| --- | --- | --- | --- | --- | --- | --- |
|  | Risk of Bias | Consistency | Directness | Precision | Other concerns |  |
| **INDUCTION OF REMISSION** | | | | | | |
| **Combination of a 6-mercaptopurine and prednisone versus prednisone alone** | | | | | | |
| 1192  (55) | Moderate | NA | Direct | Imprecise |  | Low |
| **Budesonide versus prednisolone** | | | | | | |
| 1190  (48) | Low | NA | Direct | Imprecise |  | Moderate |
| **Prednisone and mesalamine versus budesonide and mesalamine** | | | | | | |
| 1191  (33) | High | NA | Direct | Imprecise |  | Low |
| **MAINTAIN REMISSION** | | | | | | |
| **Mesalamine versus placebo** | | | | | | |
| 1194  (122) | High | NA | Direct | Imprecise |  | Low |
| **SERIOUS INFECTIONS** | | | | | | |
| **6-Mercaptopurine and prednisone versus prednisone alone** | | | | | | |
| 1192  (55) | Moderate | NA | Direct | Imprecise |  | Low |
| **OTHER INFECTIONS** | | | | | | |
| **Prednisone versus budesonide** | | | | | | |
| 1198  (120) | High | NA | Direct | Imprecise |  | Low |
| **Budesonide versus prednisolone** | | | | | | |
| 1190  (48) | Low | NA | Direct | Imprecise |  | Moderate |
| **Prednisone and mesalamine versus budesonide and mesalamine** | | | | | | |
| 1191  (33) | High | NA | Direct | Imprecise |  | Low |
| **HEIGHT CHANGE** | | | | | | |
| **6-mercaptopurine versus placebo** | | | | | | |
| 1192  (55) | Moderate | NA | Direct | Imprecise |  | Low |
| **Prednisone versus placebo** | | | | | | |
| 4196 197 199 200  (277) | High | NA | Direct | Imprecise |  | Low |
| **Prednisone versus budesonide** | | | | | | |
| 1198  (120) | High | NA | Direct | Imprecise |  | Low |
| **WEIGHT CHANGE** | | | | | | |
| **Infliximab versus placebo** | | | | | | |
| 1199  (78) | High | NA | Direct | Imprecise |  | Low |
| **Methotrexate versus placebo** | | | | | | |
| 1199  (78) | High | NA | Direct | Imprecise |  | Low |
| **Corticosteroids versus placebo** | | | | | | |
| 1199  (78) | High | NA | Direct | Imprecise |  | Low |
| **Prednisone versus budesonide** | | | | | | |
| 1198  (120) | High | NA | Direct | Imprecise |  | Low |

RCT = randomized controlled trial; NA = not applicable, consistency is not applicable when a single study reported comparison and outcome

The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.

N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not stated for each outcome.